A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space

Introduction: Cannabis extracts are being increasingly used to mitigate chronic pain. Current guidelines for their prescription rely on Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) content as well as the ratio of these major cannabinoids present in the blend. Here we assessed whether these...

Descripción completa

Detalles Bibliográficos
Autores principales: Benredjem, Besma, Pineyro, Graciela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514912/
https://www.ncbi.nlm.nih.gov/pubmed/37745077
http://dx.doi.org/10.3389/fphar.2023.1235255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514912/
https://www.ncbi.nlm.nih.gov/pubmed/37745077
http://dx.doi.org/10.3389/fphar.2023.1235255

Ejemplares similares